Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.98 million versus the consensus estimate of $2.78 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral